Altered chemokine levels in individuals at risk of Type 1 diabetes mellitus

Diabetic Medicine

Volumn 23, Issue 2, 2006, Pages 156-163

  Hanifi Moghaddam, P ^a   Kappler, S ^a   Seissler, J ^a   Muller Scholze S ^a   Martin, S ^a   Roep, B O ^b   Strassburger, K ^a   Kolb, H ^a   Schloot, N C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemokines; Cytokines; Diabetes mellitus Type 1; Pre diabetes; Serum

Indexed keywords

CHEMOKINE; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTAMATE DECARBOXYLASE; IA ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 5; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 4; PANCREAS ISLET CELL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CELLULAR IMMUNITY; CHEMOKINE BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COURSE EVALUATION; DISEASE COURSE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; IMMUNOREGULATION; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; RELATIVE; RISK FACTOR; SAMPLE SIZE; TH1 CELL; TH2 CELL; UPREGULATION;

AUTOANTIBODIES; CHEMOKINE CCL2; CHEMOKINES; CHEMOKINES, CC; COHORT STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 1; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-13; INTERLEUKIN-18; INTERLEUKIN-5; ISLETS OF LANGERHANS; MACROPHAGE INFLAMMATORY PROTEIN-1; RISK FACTORS;

EID: 33645090947     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01743.x     Document Type: Article

References (42)

1. Bingley PJ Bonifacio E Williams AJ Genovese S Bottazzo GF Gale EA. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers Diabetes 1997 46 1701 1710
2. Lernmark A. Type 1 diabetes Clin Chem 1999 45 1331 1338
3. Leslie RD Atkinson MA Notkins AL. Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes Diabetologia 1999 42 3 14
4. Maclaren N Lan M Coutant R Schatz D Silverstein J Muir A et al. Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2β predict immune-mediated (Type 1) diabetes in relatives J Autoimmun 1999 12 279 287
5. Bingley PJ Williams AJ Gale EA. Optimized autoantibody-based risk assessment in family members. Implications for future intervention trials Diabetes Care 1999 22 1796 1801
6. Pietropaolo M Becker DJ LaPorte RE Dorman JS Riboni S Rudert WA et al. Progression to insulin-requiring diabetes in seronegative prediabetic subjects: the role of two HLA-DQ high-risk haplotypes Diabetologia 2002 45 66 76
7. Charlton B Zhang MD Slattery RM. B lymphocytes not required for progression from insulitis to diabetes in non-obese diabetic mice Immunol Cell Biol 2001 79 597 601
8. Martin S Wolf R Duinkerken G Scherbaum WA Kolb H Noordzij JG et al. Development of type 1 diabetes in severe hereditary B-lymphocyte deficiency New Engl J Med 2001 345 1060 1061
9. Chiu PP Serreze DV Danska JS. Development and function of diabetogenic T-cells in B-cell-deficient non-obese diabetic mice Diabetes 2001 50 763 770
10. Holz A Dyrberg T Hagopian W Homann D von Herrath M Oldstone MB. Neither B lymphocytes nor antibodies directed against self antigens of the islets of Langerhans are required for development of virus-induced autoimmune diabetes J Immunol 2000 165 5945 5953
11. Todd JA. Genetic analysis of type 1 diabetes using whole genome approaches Proc Natl Acad Sci USA 1995 92 8560 8565
12. Lampeter EF McCann SR Kolb H. Transfer of diabetes type 1 by bone marrow transplantation Lancet I 1998 351 568 569
13. Lampeter EF Homberg M Quabeck K Wernet P Bertrams J Gries FA et al. Accidental transfer of type 1 diabetes between HLA-identical siblings by bone marrow transplantation Lancet I 1993 225 1243 1244
14. Stiller CR. Update for the Canadian multicentre trial of cyclosporine in renal allografts N Engl J Med 1984 310 1464 1465
15. Bougneres PF Carel JC Castano L Boitard C Gardin JP Landais P et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine N Engl J Med 1988 318 663 670
16. Herold KC Hagopian W Auger JA Poumian-Ruiz E Taylor L Donaldson D et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus N Engl J Med 2002 346 1692 1698
17. Bowman MA Leiter EH Atkinson MA. Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease Immunol Today 1994 15 115 120
18. Roep BO. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure Diabetologia 2003 46 305 321
19. Schloot NC Meierhoff G Karlsson FM Ott P Putnam A Lehmann P et al. Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop J Autoimmun 2003 21 365 376
20. Peakman M Tree TI Endl J van Endert P Atkinson MA Roep BO. Characterization of preparations of GAD65, proinsulin, and the islet tyrosine phosphatase IA-2 for use in detection of autoreactive T-cells in type 1 diabetes: report of phase II of the Second International Immunology of Diabetes Society Workshop for Standardization of T-cell assays in type 1 diabetes Diabetes 2001 50 1749 1754
21. Roep BO Atkinson MA van Endert PM Gottlieb PA Wilson SB Sachs JA. Autoreactive T cell responses in insulin-dependent (Type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays J Autoimmun 1999 13 267 282
22. Pradhan AD Manson JE Rifai N Buring JE Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus J Am Med Assoc 2001 286 327 334
23. Thorand B Lowel H Schneider A Kolb H Meisinger C Frohlich M et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-98 Arch Intern Med 2003 163 93 99
24. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes Diabetes Care 2004 27 813 823
25. Willerson JT Ridker PM. Inflammation as a cardiovascular risk factor Circulation 2004 109 II2 10
26. van Zeben D Breedveld FC. Prognostic factors in rheumatoid arthritis J Rheumatol Suppl 1996 44 31 33
27. Wollheim FA. Predictors of joint damage in rheumatoid arthritis APMIS 1996 104 81 93
28. Lard LR Roep BO Toes RE Huizinga TW. Enhanced concentrations of interleukin 1 6 are associated with joint destruction in patients with rheumatoid arthritis J Rheumatol 2004 31 35 39
29. Hanifi-Moghaddam P Schloot NC Kappler S Seissler J Kolb H. An association of autoantibody status and serum cytokine levels in type 1 diabetes Diabetes 2003 52 1137 1142
30. Lampeter EF Klinghammer A Scherbaum WA Heinze E Haastert B Giani G et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes Diabetes 1998 47 980 984
31. Seissler J de Sonnaville JJ Morgenthaler NG Steinbrenner H Glawe D Khoo-Morgenthaler UY et al. Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease Diabetologia 1998 41 891 897
32. Bingley PJ Bonifacio E Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation Diabetes 2003 52 1128 1136
33. Muller S Martin S Koenig W Hanifi-Moghaddam P Rathmann W Haastert B et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-α or its receptors Diabetologia 2002 45 805 812
34. Hughes AL Yeager M. Co-evolution of the mammalian chemokines and their receptors Immunogenetics 1999 49 115 124
35. Gu L Tseng S Horner RM Tam C Loda M Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1 Nature 2000 404 407 411
36. Dorner BG Scheffold A Rolph MS Huser MB Kaufmann SH Radbruch A et al. MIP-1α, MIP-1β, RANTES, and ATAC/lymphotactin function together with IFN-γ as type 1 cytokines Proc Natl Acad Sci USA 2002 99 6181 6186
37. Grob M Schmid-Grendelmeier P Joller-Jemelka HI Ludwig E Dubs RW Grob PJ et al. Altered intracellular expression of the chemokines MIP-1α, MIP-1β and IL-8 by peripheral blood CD4+ and CD8+ T cells in mild allergic asthma Allergy 2003 58 239 245
38. Daly C Rollins BJ. Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity. therapeutic opportunities and controversies Microcirculation 2003 10 247 257
39. Cameron MJ Arreaza GA Grattan M Meagher C Sharif S Burdick MD et al. Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes J Immunol 2000 165 1102 1110
40. Chase HP Cooper S Osberg I Stene LC Barriga K Norris J et al. Elevated C-reactive protein levels in the development of type 1 diabetes Diabetes 2004 53 2569 2573
41. Nicoletti F Conget I Di Mauro M Di Marco R Mazzarino MC Bendtzen K et al. Serum concentrations of the interferon-γ-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease Diabetologia 2002 45 1107 1110
42. Nicoletti F Conget I Di Marco R Speciale AM Morinigo R Bendtzen K et al. Serum levels of the interferon-γ-inducing cytokine interleukin-18 are increased in individuals at high risk of developing type I diabetes Diabetologia 2001 44 309 311